Nicox SA announced that its exclusive global licensee Bausch + Lomb has launched Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% in Taiwan. Regulatory approval in Taiwan was obtained in March 2020. Vyzulta has also recently received approval in Qatar.
In addition to Taiwan, Vyzulta is commercialized in the United States (since 2017), Canada (2019), Argentina (2020), Mexico (2020) and Hong Kong (2020), and is now approved in 5 other territories (Brazil, Colombia, Qatar, South Korea, and Ukraine). Vyzulta is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication. Bausch + Lomb will continue seeking approvals in territories where the clinical data package, part of the U.S. new drug application (NDA), can be used for approval by the regulatory authorities.
Under the terms of the exclusive global license agreement with Bausch + Lomb, Nicox receives increasing tiered royalties of 6% to 12% on net global sales of Vyzulta plus up to $150 million in potential future milestone payments.